Joerg Vollmer

Dr. Jörg Vollmer is the Chief Scientific Officer (CSO) at Abalos Therapeutics GmbH. He brings significant expertise in immunology, oncology, and infectious diseases to his role.1

Career Highlights

Dr. Vollmer has an extensive background in the biopharmaceutical industry:

• CSO at Abalos Therapeutics: His current role, where he contributes his knowledge in immunology and oncology.1
• CSO at Rigontec GmbH: Led R&D efforts and pipeline expansion, advancing a novel immuno-oncology treatment approach until the company's acquisition by MSD in 2017.1
• CEO and Managing Director at Nexigen GmbH: Developed cell-penetrating peptide therapeutics targeting tumor stem cell signaling pathways.1
• Managing Director and Site Head at Pfizer: Responsible for therapeutic oligonucleotide research and development at Pfizer's Oligonucleotide Therapeutics Unit in Düsseldorf, Germany.1
• Various positions at Coley Pharmaceutical Group: Focused on developing immune modulatory oligonucleotides targeting Toll-like receptors, rising to the position of Vice President Discovery Development before Pfizer's acquisition in 2008.1

Education and Expertise

Dr. Vollmer holds a PhD from the Max-Planck-Institute of Immunobiology, Department for Cellular Immunology in Freiburg, Germany. He studied biology at the Albert-Ludwigs-University in Freiburg.1

Additional Roles

Beyond his primary position, Dr. Vollmer serves on the Scientific Advisory Boards of Silence Therapeutics and ProteoDesign.1

Dr. Vollmer is active in the scientific community, presenting research at conferences such as the Annual Oncolytic Virotherapy Summit2 and participating in life science events.3